Table 4 Cardiotoxicity diagnosis, management, monitoring and referral to cardiac or palliative care (Medical Record Review cohort only)
From: Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
Cardiotoxicity diagnosis and management | N = 46 |
 Referred to cardiologist (any) | 27 (59) |
 Referred to cardiologist prior to first chemotherapy | 7 (15) |
 Method of cardiotoxicity diagnosisa | |
  ECG | 6 (13) |
  MUGA | 5 (11) |
  Echocardiography (LVEF < 53%) | 44 (96) |
  Angiography | 4 (9) |
 Biomarkers | Not documented |
 Monitoring during and after anticancer therapy | |
  HbA1c | 1 (2) |
  Glucose | 10 (22) |
  Systolic Blood Pressure (mmHgb) | 24 (52) |
  Diastolic Blood Pressure (mmHg) | 22 (48) |
  HR (beats per minute) | 20 (44) |
Heart failure multidisciplinary care/cardiac rehabilitation | |
 Referred to HF clinic or nurse | 22 (48) |
 Saw a HF nurse | 18 (39) |
 Referred to cardiac rehabilitation | 8 (17) |
 Attended cardiac rehabilitation | 6 (13) |
 Referred to clinical pharmacologist | 5 (11) |
 Saw a clinical pharmacologist | 4 (9) |
 Cancer survivorship or palliative care | |
  Referred to palliative care | 10 (22) |
  Received palliative care | 5 (11) |
  Cancer survivorship program referred | 1 (2) |
  Cancer survivorship program seen | 2 (4) |